Prudential plc’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,978
Closed -$365K 756
2024
Q4
$365K Hold
1,978
﹤0.01% 675
2024
Q3
$390K Hold
1,978
﹤0.01% 684
2024
Q2
$409K Buy
+1,978
New +$448K ﹤0.01% 641
2024
Q1
Sell
-2,365
Closed -$559K 775
2023
Q4
$559K Sell
2,365
-8
-0.3% -$1.57K 0.01% 753
2023
Q3
$465K Hold
2,373
0.01% 769
2023
Q2
$499K Sell
2,373
-15
-0.6% -$2.98K 0.01% 771
2023
Q1
$482K Buy
2,388
+8
+0.3% +$1.81K 0.01% 756
2022
Q4
$519K Buy
2,380
+1,237
+108% +$270K 0.01% 749
2022
Q3
$225K Buy
1,143
+130
+13% +$28.1K ﹤0.01% 783
2022
Q2
$217K Sell
1,013
-156
-13% -$38.1K ﹤0.01% 767
2022
Q1
$332K Buy
+1,169
New +$360K ﹤0.01% 699
2021
Q1
Sell
-8,115
Closed -$2.03M 599
2020
Q4
$2.03M Hold
8,115
0.01% 369
2020
Q3
$1.84M Sell
8,115
-847
-9% -$176K 0.01% 365
2020
Q2
$1.56M Buy
+8,962
New +$1.43M 0.01% 358

Other funds holding CRL

Prudential plc's CRL Position: Q1 2025 in Review

Prudential plc sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 1,978 shares — an estimated $365K sold.

Prudential plc first reported a position in CRL in Q2 2020 and held it in 14 quarters. The position peaked at $2.03M in Q4 2020. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Prudential plc reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Prudential plc sold 1,978 Charles River Laboratories shares in Q1 2025, an estimated $365K.
  • Prudential plc first reported a position in Charles River Laboratories in Q2 2020 and held it in 14 quarters.
  • Prudential plc's Charles River Laboratories position peaked at $2.03M in Q4 2020.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Prudential plc's 13F filing for Q1 2025, filed 13 May 2025.